Saltar al contenido
Merck

Dual-targeting Theranostic System with Mimicking Apoptosis to Promote Myocardial Infarction Repair

Theranostics (2017-11-22)
Jingli Chen, Jun Yang, Ruiyuan Liu, Chenmeng Qiao, Zhiguo Lu, Yuanjie Shi, Zhanming Fan, Zhenzhong Zhang, Xin Zhang
RESUMEN

Currently unsatisfactory treatment of myocardial infarction (MI) is due to the unbridled inflammation and the delayed diagnosis at the early stage. To address these problems, firstly, phosphatidylserine (PS) was used to modulate the phenotypes of macrophages (MΦ) and resolve the early inflammation

MATERIALES
Referencia del producto
Marca
Descripción del producto

Sigma-Aldrich
Ácido oleico, technical grade, 90%
Sigma-Aldrich
Tin(II) 2-ethylhexanoate, 92.5-100.0%
Sigma-Aldrich
α-Bromoisobutyryl bromide, 98%
Sigma-Aldrich
N,N,N′,N′′,N′′-Pentamethyldiethylenetriamine, 99%
Sigma-Aldrich
(3S)-cis-3,6-Dimethyl-1,4-dioxane-2,5-dione, 98%
Sigma-Aldrich
Biphenyl-4-carboxylic acid, 95%
Sigma-Aldrich
2-Hydroxyethyl 2-bromoisobutyrate, 95%
Sigma-Aldrich
3,3′-Diiodo-L-thyronine (T2) hydrochloride, 98% (CP)